Download App

Log in to access Online Inquiry
Company Overview More
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson’s disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
CEO: Mates Ph.D., Sharon
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

ITCI Intra-Cellular Therapies

57.880+0.150+0.26%
Close 05/20 20:00 ET
57.88000.00%
Post Mkt Price 05/20 16:28 ET
High
59.850
Open
58.500
Turnover
50.26M
Low
55.550
Pre Close
57.730
Volume
873.85K
Market Cap
5.46B
P/E(TTM)
Loss
52wk High
66.000
Shares
94.32M
P/E(Static)
Loss
52wk Low
28.400
Float Cap
5.01B
Bid/Ask %
-20.00%
Historical High
66.000
Shs Float
86.55M
Volume Ratio
0.88
Historical Low
6.750
Dividend TTM
--
Div Yield TTM
1900
P/B
6.89
Dividend LFY
--
Div Yield LFY
3282.65%
Turnover Ratio
1.01%
Amplitude
7.45%
Avg Price
57.509
Lot Size
1
Float Cap
5.01B
Bid/Ask %
-20.00%
Historical High
66.000
Shs Float
86.55M
Volume Ratio
0.88
Historical Low
6.750
Dividend TTM
--
P/B
6.89
Dividend LFY
--
Turnover Ratio
1.01%
Amplitude
7.45%
Avg Price
57.509
Lot Size
1
Price Forecast

No Data

News

Comment